MENLO PARK, Calif.,
March 2, 2017 /PRNewswire/
-- BioPharmX Corporation (NYSE MKT: BPMX), a specialty
pharmaceutical company developing products for the dermatology
market, will share early clinical and pre-clinical data at the 2017
American Academy of Dermatology (AAD) Annual Meeting, which will
show the company's novel topical gel BPX-01 may deliver
acne-fighting medication to a target area without side effects.
A poster sharing the research, titled "Development and
Assessment of BPX-01, a Novel Topical Minocycline Gel for Treatment
of Acne Vulgaris," will be available for viewing at the event
March 3-6. In addition, BioPharmX
Senior Director of Preclinical Drug Development Usha Nagavarapu
will deliver a presentation based on the poster on March 3 at 10:10
a.m. The AAD meeting, being held in Orlando, Fla., is one of the world's largest
gatherings of dermatologists.
Oral minocycline is routinely prescribed for the treatment of
acne, but because the drug is delivered systemically, undesirable
side effects, such as upset stomach, diarrhea, dizziness and
headache often result. BPX-01 is the first topical gel formulation
of minocycline, which may enable the use of a much lower dosage of
drug, and which clinical and pre-clinical studies suggest thus far
does not enter the blood system in measurable quantities.
"The 'Holy Grail' in acne treatment is optimizing both efficacy
and tolerability," said Dr. Ted
Lain, board certified dermatologist and investigator on the
BioPharmX Phase 2b study of BPX-01. "What dermatologists
desperately need is a product with both a very limited side effect
profile and reliable efficacy comparable to that of oral
antibiotics."
BPX-01[1] is the first and only stable hydrophilic
(non-oil-based) topical gel with fully solubilized minocycline that
can penetrate the skin to deliver the antibiotic to where acne
develops in the pilosebaceous unit. The company's studies are
designed to confirm whether BPX-01 can effectively treat acne with
lower, and potentially safer, dosages of the antibiotic.
"The research to date shows that BPX-01 topical gel may
effectively and safely deliver minocycline to target areas," said
Kin F. Chan, executive vice president of research and technology at
BioPharmX. "The studies so far offer promise to millions of people
who cannot take oral minocycline to treat their acne, including the
many individuals who are intolerant of systemic antibiotic
treatments."
BioPharmX is currently conducting an OPAL (tOPicAL Minocycline
Gel) study – a Phase 2b dose finding clinical trial to assess the
efficacy and safety of BPX-01 for the treatment of acne vulgaris.
The 12-week, multi-center, randomized, double-blind, three-arm,
vehicle-controlled study involves 225 individuals, aged 9 to 40,
who have moderate-to-severe inflammatory, non-nodular acne
vulgaris.
The AAD calls acne the "most common skin condition in the United
States," affecting 40 million to 50 million Americans. The U.S.
market for prescription acne medications is estimated at
$4 billion.
About BioPharmX® Corporation
BioPharmX Corporation
(NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical
company that seeks to provide products through proprietary platform
technologies for prescription, over-the-counter and supplement
applications in dermatology and women's health. To learn more about
BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statement
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the "safe harbor" created by those
sections. This press release contains forward-looking statements
about the company's expectations, plans, intentions and strategies,
including, but not limited to, statements regarding, whether BPX-01
will deliver acne-fighting medication to a target area without side
effects, whether BPX-01 will enable the use of a much lower dosage
of minocycline, whether topical minocycline enters the blood system
in measurable quantities, and whether BPX-01 can effectively treat
acne with lower, and potentially safer, dosages of the antibiotic.
These forward-looking statements may be identified by words such as
"may", "plan", "expect," "anticipate," "believe," or similar
expressions that are intended to identify such forward-looking
statements. These forward-looking statements involve risks and
uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause our results to differ
materially from those expressed or implied by such forward-looking
statements. The risks and uncertainties include those described in
the company's filings with the Securities and Exchange Commission.
Given these risks and uncertainties, you are cautioned not to place
undue reliance on such forward-looking statements. The
forward-looking statements included in this news release are made
only as of the date hereof and the company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as may be required under applicable securities laws.
BioPharmX is a registered trademark of BioPharmX, Inc.
[1] Caution: BPX-01 is a new drug
limited by federal or U.S. law to investigational use.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biopharmx-presents-poster-at-american-academy-of-dermatology-annual-meeting-suggesting-bpx-01-safely-efficiently-delivers-acne-fighting-minocycline-to-pilosebaceous-units-300415801.html
SOURCE BioPharmX Corporation